These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 30554492)

  • 1. Antithrombotic Medication and the Risk of Vitreous Hemorrhage in Atrial Fibrillation: Korean National Health Insurance Service National Cohort.
    Kim KE; Yang PS; Jang E; Kim S; Joung B
    Yonsei Med J; 2019 Jan; 60(1):65-72. PubMed ID: 30554492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation.
    Kang DO; Yu CW; Kim HD; Cho JY; Joo HJ; Choi RK; Park JS; Lee HJ; Kim JS; Park JH; Hong SJ; Lim DS
    Coron Artery Dis; 2015 Aug; 26(5):372-80. PubMed ID: 25768244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
    Choi HI; Ahn JM; Kang SH; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1075-1085. PubMed ID: 28527773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    Lopes RD; Rao M; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Hylek EM; Kowey P; Piccini JP; Singer DE; Chang P; Peterson ED; Mahaffey KW
    Am J Med; 2016 Jun; 129(6):592-599.e1. PubMed ID: 26797080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Antithrombotic Therapy versus Anticoagulant Monotherapy for Major Adverse Limb Events in Patients with Concomitant Lower Extremity Arterial Disease and Atrial Fibrillation: A Propensity Score Weighted Analysis.
    Lin DS; Wu HP; Chung WJ; Hsueh SK; Hsu PC; Lee JK; Chen CC; Huang HL
    Eur J Vasc Endovasc Surg; 2024 Oct; 68(4):498-507. PubMed ID: 38754724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation.
    Guo Y; Wang H; Tian Y; Wang Y; Lip GYH
    Chest; 2015 Jul; 148(1):62-72. PubMed ID: 25501045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement.
    Abdul-Jawad Altisent O; Durand E; Muñoz-García AJ; Nombela-Franco L; Cheema A; Kefer J; Gutierrez E; Benítez LM; Amat-Santos IJ; Serra V; Eltchaninoff H; Alnasser SM; Elízaga J; Dager A; García Del Blanco B; Ortas-Nadal Mdel R; Marsal JR; Campelo-Parada F; Regueiro A; Del Trigo M; Dumont E; Puri R; Rodés-Cabau J
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1706-17. PubMed ID: 27539691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study.
    Chan EW; Lau WC; Siu CW; Lip GY; Leung WK; Anand S; Man KK; Wong IC
    Heart Rhythm; 2016 Aug; 13(8):1581-8. PubMed ID: 27033342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The optimal antithrombotic strategy for post-stroke patients with atrial fibrillation and extracranial artery stenosis-a nationwide cohort study.
    Tsai CT; Chan YH; Liao JN; Chen TJ; Lip GYH; Chen SA; Chao TF
    BMC Med; 2024 Mar; 22(1):113. PubMed ID: 38475752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal Antithrombotic Therapy Beyond 1-Year After Coronary Revascularization in Patients With Atrial Fibrillation.
    Kim J; Kang D; Kim H; Park H; Park TK; Lee JM; Yang JH; Song YB; Choi JH; Choi SH; Gwon HC; Guallar E; Cho J; Hahn JY
    J Korean Med Sci; 2024 Jun; 39(24):e191. PubMed ID: 38915283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anticoagulation status and adherence in patients with atrial fibrillation hospitalized for ACS and the impact on 1-year prognosis: a multicenter cohort study].
    Zhu LY; Li Q; Yu LY; Liu Y; Chen YN; Wang Z; Zhang SY; Li J; Liu Y; Zhao YL; Xi Y; Pi L; Sun YH
    Zhonghua Xin Xue Guan Bing Za Zhi; 2023 Jul; 51(7):731-741. PubMed ID: 37460427
    [No Abstract]   [Full Text] [Related]  

  • 12. Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National Acute Stroke Israeli Survey [NASIS]).
    Schwammenthal Y; Bornstein N; Schwammenthal E; Schwartz R; Goldbourt U; Tsabari R; Koton S; Grossman E; Tanne D
    Am J Cardiol; 2010 Feb; 105(3):411-6. PubMed ID: 20102959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.
    Thompson PL; Verheugt FW
    Clin Ther; 2014 Sep; 36(9):1176-81. PubMed ID: 25234549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients.
    Shireman TI; Howard PA; Kresowik TF; Ellerbeck EF
    Stroke; 2004 Oct; 35(10):2362-7. PubMed ID: 15331796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Warfarin Use in Patients With Atrial Fibrillation Undergoing Hemodialysis: A Nationwide Population-Based Study.
    Yoon CY; Noh J; Jhee JH; Chang TI; Kang EW; Kee YK; Kim H; Park S; Yun HR; Jung SY; Oh HJ; Park JT; Han SH; Kang SW; Kim C; Yoo TH
    Stroke; 2017 Sep; 48(9):2472-2479. PubMed ID: 28801476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy.
    van Rein N; Heide-Jørgensen U; Lijfering WM; Dekkers OM; Sørensen HT; Cannegieter SC
    Circulation; 2019 Feb; 139(6):775-786. PubMed ID: 30586754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.
    Chi G; Yee MK; Kalayci A; Kerneis M; AlKhalfan F; Mehran R; Bode C; Halperin JL; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Peterson ED; Fox KAA; Gibson CM
    J Thromb Thrombolysis; 2018 Oct; 46(3):346-350. PubMed ID: 29943350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1.
    Lee BH; Park JS; Park JH; Park JS; Kwak JJ; Hwang ES; Kim SK; Choi DH; Kim YH; Pak HN
    J Cardiovasc Electrophysiol; 2010 May; 21(5):501-7. PubMed ID: 20021521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Impact of different antithrombotic therapy strategy on prognosis in coronary heart disease patients combining with atrial fibrillation: a meta analysis].
    Yuan C; Zhong L; Huang RC
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Jun; 45(6):526-535. PubMed ID: 28648031
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
    Larsen TB; Rasmussen LH; Skjøth F; Due KM; Callréus T; Rosenzweig M; Lip GY
    J Am Coll Cardiol; 2013 Jun; 61(22):2264-73. PubMed ID: 23562920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.